Latest Pseudomonas Stories

The bacterium, called Pseudomonas aeruginosa, is the most common cause of persistent and fatal lung infections in cystic fibrosis patients. Scientists at Liverpool identified a particularly virulent strain of the bacteria that is transmissible between patients. The Liverpool Epidemic Strain (LES), referred to as a cystic fibrosis 'superbug', can cause aggressive infection and results in progressive lung decline.The team from the University's Institute of Infection and Global Health took...

Researchers funded by the Biotechnology and Biological Sciences Research Council (BBSRC) have revealed a novel molecular mechanism that triggers plant infection by Pseudomonas syringae, the bacteria responsible for bacterial speck in tomatoes. The scientists from the Department of Life Sciences at Imperial College London have revealed how two genes in the bacteria work together to launch the infection process that ultimately kills the plant's cells and causes disease, significantly reducing...

Researchers at National Jewish Health and the University of Texas Southwestern Medical Center have discovered a new method to fight bacterial infections associated with contact lenses. The method may also have applications for bacterial infections associated with severe burns and cystic fibrosis. The results were published online January 18 in the journal Investigative Ophthalmology and Visual Science."Infections by the bacteria Pseudomonas aeruginosa can cause severe scarring and vision loss...

WOBURN, Mass. and VEDBAEK, Denmark, Jan. 17, 2011 /PRNewswire/ -- AdvanDx today announced that it has received FDA 510(k) clearance for its GNR Traffic Light(TM) PNA FISH(R) test. GNR Traffic Light PNA FISH is the first test capable of simultaneously identifying Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa directly from positive blood cultures containing Gram-negative rods in less than 90 minutes. The test is the latest addition to AdvanDx's easy-to-use,...

SAN FRANCISCO, Jan. 10, 2011 /PRNewswire/ -- Mpex Pharmaceuticals, Inc. today during the JP Morgan 29th Annual Healthcare Conference, announced that it has initiated its Phase 3 clinical trial program with Aeroquin(TM) (MP-376) for the treatment of pulmonary infections in patients with cystic fibrosis (CF). Aeroquin is Mpex's proprietary aerosol formulation of levofloxacin, an antibiotic that has potent activity against key bacterial pathogens in CF including Pseudomonas aeruginosa. The...

Genetic resistance to antibiotics is not the only trick bacteria use to resist eradication"“ they also have a second defence strategy known as persistence that can kick in.Researchers reporting in the Journal of Medical Microbiology have now demonstrated for the first time that interplay occurs between the two mechanisms to aid bacterial survival. The findings could lead to novel, effective approaches to treat multi-drug resistant (MDR) infections.'Persister' bacterial cells are temporarily...

Cold plasma jets could be a safe, effective alternative to antibiotics to treat multi-drug resistant infections, says a study published in the January issue of the Journal of Medical Microbiology on 15 December.The team of Russian and German researchers showed that a ten-minute treatment with low-temperature plasma was not only able to kill drug-resistant bacteria causing wound infections in rats but also increased the rate of wound healing. The findings suggest that cold plasmas might be a...

Joint press release from NWO and TU Delft Researcher Jean-Paul Meijnen has 'trained' bacteria to convert all the main sugars in vegetable, fruit and garden waste efficiently into high-quality environmentally friendly products such as bioplastics. He will be defending his doctoral thesis on this topic, which was carried out in the context of the NWO B-Basic programme, at TU Delft on Monday 22 November 2010.There is considerable interest in bioplastics nowadays. The technical problems...

VIENNA, Oct. 25 /PRNewswire-FirstCall/ -- Intercell AG (VSE: ICLL) today announced results from a Phase II clinical trial involving the company's investigational nosocomial vaccine candidate (IC43) against infections with the bacterium Pseudomonas aeruginosa, a leading cause of hospital-acquired infections with increasing antibiotic resistance and hence a very high unmet medical need. In the randomized, controlled Phase II clinical trial (33 sites in 8 countries), about 400 mechanically...

MONMOUTH JUNCTION, N.J., Oct. 21 /PRNewswire/ --Transave, Inc., today reported positive clinical trial results on its lead investigational drug, ARIKACE(TM) (liposomal amikacin for inhalation), an antibiotic that is entering Phase III development for the treatment of chronic lung infections. The results demonstrate significant clinical benefit and complete the company's Phase II program for the treatment of lung infections due to the bacterium, Pseudomonas aeruginosa in cystic fibrosis...